Independent, CME-Accredited symposium

Thursday, May 6, 2021 – 13:30-15:00 CEST
Chaired by Mohamad Mohty
With Saad Usmani, Noopur Raje, Luciano Costa, Marc Labetoulle

This independent symposium, led by a faculty comprising international key opinion leaders, aims to give the target audience of hematologists, oncologists, oncology nurses, and healthcare professionals the necessary tools to identify and manage toxicity issues associated with new multiple myeloma treatments.

You will have the opportunity to pose questions live to the faculty.

Learning Objectives

After participating in the symposium, you will be able to:

  • Identify and explain toxicity issues related to new treatments for multiple myeloma
  • Debate how to appropriately manage multiple myeloma-related cardiovascular toxicities
  • Discuss and analyze the advances in the management of cytokine-release syndrome, neurotoxicities, and ocular toxicities, caused by novel treatments like CAR-T cell therapy and antibody–drug conjugates


13:30 Introduction
Mohamad Mohty, France
13:35 Managing multiple myeloma-related cardiotoxicities
Saad Usmani, USA
13:50 Managing cytokine release syndrome after CAR-T cell therapy
Noopur Raje, USA
14:05 Managing neurotoxicities after CAR-T cells and T cell engagers
Luciano Costa, USA
14:20 Managing ocular adverse events after antibody drug-conjugates
Marc Labetoulle, France
14:35 Panel discussion & Q&A
14:55 Summary and closing
Mohamad Mohty, France


Mohamad Mohty

Professor of Hematology and Head of the Hematology and Cellular Therapy Department, Saint-Antoine Hospital and Sorbonne University, Paris, France

Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University, Paris, France. Professor Mohty is also head of a translational research team at the Saint-Antoine Research Centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma. Professor Mohty is past-president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and serves on the board of the EBMT, and the Intergroupe Francophone du Myelome (IFM). He is also a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation, European Hematology Association (EHA), and EBMT.

Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. He has published more than 700 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International, and as Associate Editor for Leukemia and the European Journal of Haematology.


Grants/research support, honoraria/consultation fees from: Amgen, Celgene, Takeda, Sanofi, Janssen, Jazz Pharmaceuticals

Saad Z Usmani

Division Chief, Plasma Cell Disorders Division; Director, Clinical Research in Hematologic Malignancies; Clinical Professor of Medicine, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA

Saad Zafar Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a Fellowship in Hematology and Oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr Usmani joined the faculty of the Levine Cancer Institute in July 2013; he also currently holds an academic appointment as Clinical Professor of Medicine at the University of North Carolina-Chapel Hill School of Medicine. Previously, Dr Usmani served as Assistant Professor of Medicine at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, and Director of Developmental Therapeutics at the Myeloma Institute for Research and Therapy.

Dr Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership of several professional societies, including the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. Dr Usmani has served as the Track Leader on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, and he is the Chair of the ASH Committee on Plasma Cell Neoplasia and a member of the National Cancer Institute Myeloma Steering Committee. Dr Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 170 peer-reviewed research manuscripts and 220 abstracts at national and international meetings. Active in clinical and translational research, Dr Usmani has research interests focused on plasma cell disorders – in particular, high-risk multiple myeloma.



Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Consulting: Amgen, BMS, Celgene, EdoPharma, GSK, Janssen, Sanofi, Seattle Genetics

Noopur Raje

Director, Center for Multiple Myeloma, Boston, MA, USA

Noopur Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the Massachusetts General Hospital (Mass General) Cancer Center, Dr Raje leads a dedicated clinical team engaged in investigator-initiated, multicenter, national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at Mass General, with her laboratory’s efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr Raje received her medical degree from B.J. Medical College, Pune University in India, trained in Internal Medicine at Mass General and subsequently completed a Fellowship in Hematology and Medical Oncology in the joint Mass General-Brigham and Women’s-Dana-Farber program. She is an Associate Professor of Medicine at Harvard Medical School and the Rita M Kelley Chair in Oncology at Mass General. She is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award, and the Claflin Distinguished Scholar Award.


Grants/research support, honoraria/consultation fees from: Bluebird Bio, Celgene, Takeda, Amgen, BMS, Karyopharm, Imuneel, Caribou Biosciences

Luciano J Costa

Professor of Medicine, Director of the Multiple Myeloma Program, O’Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA

Luciano Costa obtained a medical degree and subsequently PhD from Universidade de Sao Paulo, Brazil. He trained in Hematology and Medical Oncology at University of Colorado and in Blood and Marrow Transplantation at Mayo Clinic, Rochester, Minnesota, US. He is currently Professor of Medicine and Senior Clinical Investigator at University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, where he is also Director of the Multiple Myeloma Research and Treatment Program and serves as Associate Cancer Center Director for Clinical Research. Dr Costa leads several multi-institutional and international projects exploring new cellular and immunotherapies and minimal residual disease in myeloma. He is regarded as an international leader in the field with more than 200 peer-reviewed abstracts and publications in high-impact journals such as Blood, Leukemia, the Journal of Clinical Oncology, and The New England Journal of Medicine.


Grants/research support, honoraria/consultation fees from: Amgen, Janssen, BMS, Sanofi, Karyopharm, AstraZeneca

Marc Labetoulle

Professor and Chairman of Ophthalmology, Paris-Saclay University, Bicêtre Hospital, Le Kremlin-Bicêtre, France

Marc Labetoulle graduated as a physician and specialist in Ophthalmology in 1994 at the Paris-Descartes University. After his graduation, he served successively as Resident, Assistant, Associate Professor, and Professor in the same department of Ophthalmology. During this period, he also spent 2 years as full-time researcher (1994–1995 and 1999–2000) in the Virology Department of CNRS (Gif-sur-Yvette), where he was Head of the “HSV Latency” team for 15 years, before moving his experimental research activity to the Center for Immunology of Viral Infections and Autoimmune Diseases (IMVA, CEA, Université Paris Saclay, Inserm U1184). Together with his team, he continues his experimental research on the balance between latency and reactivation of Herpes simplex virus type 1 (HSV1) in the nervous system and then in the ocular tissues. Professor Labetoulle also plays an important role in clinical research in the field of immune and infectious disorders of the eye, especially those of the ocular surface (cornea and conjunctiva), either infectious or inflammatory. For the last 20 years, he has been involved in more than 55 clinical trials, including 8 as the Principal Investigator. He authored more than 200 peer-reviewed publications in international ophthalmic journals.


Grants/research support, honoraria/consultation fees from: Alcon, Allergan, Bausch & Lomb, DMC, Dompe, GSK, Horus, MSD, Novartis, Quantel, Santen, Shire, Sifi, Thea, Topivert


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NACCME designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.


NACCME designates the live activity; a maximum of 1.5 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to claim your credits

To claim your credits for participating in the accredited activity, you will need to take part in the full live session, then fill out the short evaluation form at the end of the activity and complete the appropriate details.

Disclosure of relevant financial relationships

Disclosure of relevant financial relationships

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Planning Committee

In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Greaton Sellers, Philly Morris-Jones, Alba Ruzafa and Marie Le Solliec. The Planning Committee have no financial relationships to disclose.

Educational grant

Independent symposium organized by Springer Healthcare IME. This educational activity is supported by an educational grant from GlaxoSmithKline which is intended for healthcare professionals outside of the United States.